ALLSCHWIL, SWITZERLAND - 23 September 2015 - Actelion Ltd (ATLN.VX) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®) will be shared through an oral presentation at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands.
The oral presentation, titled `Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results` will be given by Professor Olivier Sitbon from the Hospital Le Kremlin Bicêtre, Paris, France, at 11.15 on 30 September. The abstract can be found in the congress program online.
The ERS Congress will also see the presentation of further information on macitentan (Opsumit®), with a poster titled `Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives`. The poster will be presented in a poster discussion session by Dr Noémie Hurst from 10.45 on 28 September. The abstract can be found in the congress program online.
###
Notes to Editor:
SELEXIPAG AT ERS-15
Oral presentation:
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
O. Sitbon, R. Channick, K. Chin, A. Frey, N. Galiè, H.-A. Ghofrani, M.M. Hoeper, I. Lang, F.-O. Le Brun, V. McLaughlin, R. Preiss, L.J. Rubin, G. Simonneau, V. Tapson, S. Gaine
Wednesday, September 30, 11:15 - 11:30, Room 4.1
MACITENTAN AT ERS-15
Poster presentation:
Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives
N. Hurst. M. Pellek, P.N. Sidharta, J. Dingemanse
Monday, September 28, 10:45 - 12:45, Room E102
ACTELION LTD
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland